Abstract
The C-aryl glucoside 6 (dapagliflozin) was identified as a potent and selective hSGLT2 inhibitor which reduced blood glucose levels in a dose-dependent manner by as much as 55% in hyperglycemic streptozotocin (STZ) rats. These findings, combined with a favorable ADME profile, have prompted clinical evaluation of dapagliflozin for the treatment of type 2 diabetes.
MeSH terms
-
Administration, Oral
-
Animals
-
Benzhydryl Compounds
-
Blood Glucose / metabolism
-
Diabetes Mellitus, Experimental / drug therapy
-
Diabetes Mellitus, Type 2 / drug therapy*
-
Glucosides / chemical synthesis*
-
Glucosides / chemistry
-
Glucosides / pharmacology
-
Humans
-
Hypoglycemic Agents / chemical synthesis*
-
Hypoglycemic Agents / chemistry
-
Hypoglycemic Agents / pharmacology
-
Kidney / metabolism*
-
Rats
-
Sodium-Glucose Transporter 2
-
Sodium-Glucose Transporter 2 Inhibitors*
-
Stereoisomerism
Substances
-
Benzhydryl Compounds
-
Blood Glucose
-
Glucosides
-
Hypoglycemic Agents
-
SLC5A2 protein, human
-
Sodium-Glucose Transporter 2
-
Sodium-Glucose Transporter 2 Inhibitors
-
dapagliflozin